Management of Hypotension in Heart Failure

Introduction to Midodrine

Midodrine works as a peripheral alpha-1 adrenergic agonist that increases peripheral vascular resistance, maintains central blood volume and cardiac output, and provides vasopressor support without direct cardiac effects 1
The American Journal of Kidney Diseases recommends midodrine as a treatment option for hypotension in patients with systolic heart failure, with a starting dose of 2.5-5 mg orally, and timing of administration usually 30 minutes before dialysis sessions in renal patients, or 2-3 times daily in heart failure patients, avoiding evening doses to prevent supine hypertension 1

The typical dosage of midodrine for heart failure patients is 2.5-5 mg orally, 2-3 times daily, with titration based on blood pressure response 1
Midodrine should be administered with caution in heart failure patients, avoiding evening doses to prevent supine hypertension during sleep, and monitoring for side effects such as piloerection, scalp itching, nausea, heartburn, urinary urgency, and headache 1

Midodrine can cause supine hypertension in <10% of patients, and should be used with caution in patients with bradycardia due to reflex parasympathetic stimulation 1
The American Journal of Kidney Diseases recommends using midodrine cautiously with beta-blockers, digoxin, and non-dihydropyridine calcium channel blockers, and avoiding combination with other alpha-adrenergic agents (ephedrine, pseudoephedrine) 1
Midodrine is cleared by hemodialysis with a reduced half-life of 1.4 hours during dialysis, and its use requires careful monitoring to balance the benefits against potential risks 1

Midodrine may be particularly useful in patients unable to tolerate target doses of guideline-directed medical therapy (GDMT) due to hypotension, advanced heart failure patients with refractory hypotension, patients transitioning from IV vasopressors to oral therapy, and heart failure patients with preserved ejection fraction (HFpEF) who require diuretics despite hypotension, although these uses are not supported by the provided citation 1
Patients should be identified as candidates for midodrine if they have systolic heart failure with hypotension limiting GDMT, and should undergo baseline assessment, initiation of midodrine, monitoring of response, and titration of GDMT, with periodic reassessment of the need for midodrine 1